Browse 79 market data Tables and 60 Figures spread through 184 Pages and in-depth TOC on "HLA Typing for Transplant Market by Technology (SSO-PCR, SSP-PCR, NGS, Sanger’s Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) - Forecast to 2021"
- Advertising -
The report "HLA Typing for Transplant Market by Technology (SSO-PCR, SSP-PCR, NGS, Sanger’s Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) - Forecast to 2021" , analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
The Global HLA Typing for Transplant Market Is Projected to reach USD 753.9 Million by 2021 From USD 535.0 Million in 2016, at a CAGR of 7.1%, during 2016 to 2021
Full Report : www.marketsandmarkets.com/Market-R…ket-96374742.html
On basis of technology, the HLA typing for transplant market is categorized into molecular assay technology [including PCR-based (Sequence-specific oligonucleotide and sequence-specific primer-PCR) and sequencing-based (next-generation sequencing and Sanger sequencing)] and non-molecular assay technology (includes serological and mixed lymphocyte culture assays). The molecular assay segment is expected to account for the larger share of the global HLA typing for transplant market in 2016.
The sequencing-based molecular assay segment is projected to grow faster than the PCR-based molecular assay segment, growing at a double-digit CAGR during 2016–2021.
- Advertising -
The PCR-based molecular assay segment is expected to hold a larger share of the global HLA typing for transplant market for molecular assay technology in 2016.
Factors such as growing number of solid organ, soft tissue, and stem cell transplantations; technological advancements; and increased funding, research grants, and public-private investments are the key market drivers for the HLA-based transplant diagnostics industry. However, high device costs associated with NGS and PCR-based devices and limited medical reimbursements for organ donation and transplantation procedure restrain the growth of the market to a certain extent.
Furthermore, the technological shift from serological assays to gene-based HLA profiling and improving healthcare infrastructure across developing countries provide opportunities for players in the HLA typing for transplant market. The significant gap between the number of organs donated and the number of organs required annually is a major challenge limiting the growth of the global HLA typing for transplant market.
In 2016, North America and Europe are expected to be the mature markets for HLA typing products for transplant. However, emerging regions such as Asia-Pacific (including Japan, China, and India) are expected to become the new revenue-generating pockets in the HLA typing for transplant market in the next five years.
The North America is expected to hold the largest share of the global HLA typing for transplant market in 2016; it is projected to grow at the highest CAGR during the forecast period owing to easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, increasing prevalence of target diseases (such as cancer, heart failure, and renal diseases) in the U.S. and Canada, and continuous technological advancements in the field of HLA-based transplant diagnostics.
As of 2015, the key players in the HLA typing for transplant market included Thermo Fischer Scientific, Inc. (U.S.), Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc.
(Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc.
(U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc.
(U.S.), among others.
Category: Market Research Publishers and RetailersCompany profile: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...
For more information: